Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$180.96 USD
+2.38 (1.33%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$180.96 USD
+2.38 (1.33%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Duke Energy (DUK) Brand Starts Building 250MW Solar Project
by Zacks Equity Research
Duke Energy (DUK) announces the 250-MW Pisgah Ridge Solar project will supply power to three corporations, once its construction is completed by 2022-end.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ETF Strategies to Hedge Against Inflation
by Neena Mishra
Here are some ways to protect your portfolio from rising inflation.
Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.
Company News for Feb 18, 2021
by Zacks Equity Research
Companies in the news are: CRL, VIR, LODE, CLPS
Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?
by Zacks Equity Research
Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).
Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings
by Zacks Equity Research
LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.
Why Charles River (CRL) Could Beat Earnings Estimates Again
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Growth Investors Will Love Charles River (CRL)
by Zacks Equity Research
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
by Zacks Equity Research
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Charles River Laboratories (CRL) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More
by Zacks Equity Research
The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.
Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?
by Zacks Equity Research
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
by Zacks Equity Research
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
Moving Average Crossover Alert: Charles River Laboratories International
by Zacks Equity Research
Charles River Laboratories International, Inc. (CRL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.